*Five Years Citation in Google scholar (2016 - 2020) is. 1451*   *    IJPR IS INDEXED IN ELSEVIER EMBASE & EBSCO *       

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence
Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
No Data found.
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
Impact of different patient diseases on authorized generic change

Author: ATSUSHI ISHIMURA, MAYUMI TOMIZAKI
Abstract: Aging is a global challenge, with rapid progress in both developed and developing countries. Healthcare costs continue to increase, and many countries are pursuing policies to reduce them through cheaper generic equivalent (GE) medicines. In the USA, there is an authorized generic (AG) system under which a GE identical to an original drug can be launched with a patent license of the original drug. AG has recently been introduced in Japan, and its use is expected to be promoted to reduce medical costs. Previously, we conducted a survey on AG modification for those wishing to use original medicines and found that modification was possible in 50% of patients. However, there has been no research on whether different diseases affect AG changes; therefore, we conducted a survey on AG changes using two medicines with different indications. Patients who were prescribed amlodipine (for hypertension) or rosuvastatin (for hypercholesterolemia) at an insurance pharmacy were included, and the number and age of patients requesting the original drug and AG were compared. The results showed no difference in the age or proportion of patients who preferred the original drug; however, those who preferred the original drug but could change if it was an AG were more likely to be on amlodipine, suggesting that different diseases may lead to differences in the selectivity for AGs. In addition to being an AG, the reason for this could be that the drug names of the original and generic drugs were similar.
Keyword: Authorized generics, Generic medicines, Aging population, Healthcare costs
DOI: https://doi.org/10.31838/ijpr/2024.16.03.002
Download: Request For Article
 
Clients

Clients

Clients

Clients

Clients
ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
News & Events
SCImago Journal & Country Rank

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free